US FDA declines to approve Regeneron's blood cancer therapy for second time – Reuters

Written by

admin

in

  1. US FDA declines to approve Regeneron’s blood cancer therapy for second time  Reuters
  2. Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up  TradingView
  3. Regulatory Roadblocks Blemish Regeneron’s Otherwise Strong Q2  BioSpace
  4. Regeneron’s (NASDAQ:REGN) Q2: Strong Sales  FinancialContent
  5. Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates  Yahoo Finance

Continue Reading

More posts